Cervical Intraepithelial Neoplasia- Pipeline Insight, 2025

DelveInsight’s, “Cervical Intraepithelial Neoplasia- Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Cervical Intraepithelial Neoplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cervical Intraepithelial Neoplasia: Understanding

Cervical Intraepithelial Neoplasia: Overview

Cervical Intraepithelial Neoplasia (CIN), also known as cervical dysplasia is a precancerous condition in which abnormal cells grow on the surface of the cervix. Cervical Intraepithelial Neoplasia results from HPV infection within cervical cells. These changes, especially in young women, commonly revert to normal cells due to an intact immune response and rapid turnover of cells on the cervix. Cervical Intraepithelial Neoplasia may be classified according to how much epithelial tissue is affected: Low-grade neoplasia (CIN 1) refers to dysplasia that involves about one-third of the thickness of the epithelium, CIN 2 refers to abnormal changes in about one-third to two-thirds of the epithelial layer, CIN 3 (the most severe form) describes a condition that affects more than two-thirds of the epithelium. About 60% of CIN-1 will regress to normal after 1 year. Women with CIN-2 and CIN-3 are at high risk for developing invasive cancer, although the average time for progression is still several years.

The pap smear is responsible for decreasing the incidence of and mortality rates from cervical cancer. The Papanicolaou (Pap) smear is a collection of cells from the squamocolumnar junction of the cervix where the columnar epithelium is juxtaposed to the smooth squamous epithelium. In this area, squamous metaplasia is causing squamous cells to replace columnar cells. This cell growth and change can allow the entrance of human papillomavirus (HPV), the cause of more than 90% of cervical cancer. The Pap smear is a sample of cells from this area to screen a patient for abnormalities such as cervical dysplasia.

In most instances, dysplastic lesions of the cervix are not visible to the naked eye, and it is the Pap smear that detects abnormalities requiring further evaluation. Colposcopy with directed biopsy is the preferred method for evaluation of an abnormal Pap smear result. In the case of moderate and severe CIN, treatment focuses on the removal of abnormal cells that might become cancerous.

""Cervical Intraepithelial Neoplasia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical Intraepithelial Neoplasia pipeline landscape is provided which includes the disease overview and Cervical Intraepithelial Neoplasia treatment guidelines. The assessment part of the report embraces, in depth Cervical Intraepithelial Neoplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical Intraepithelial Neoplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cervical Intraepithelial Neoplasia R&D. The therapies under development are focused on novel approaches to treat/improve Cervical Intraepithelial Neoplasia.

Cervical Intraepithelial Neoplasia Emerging Drugs Chapters

This segment of the Cervical Intraepithelial Neoplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical Intraepithelial Neoplasia Emerging Drugs

• VGX-3100: Inovio Pharmaceuticals

INOVIO’s product candidate VGX-3100 is designed to significantly increase T cell immune responses against the E6 and E7 antigens of HPV types 16 and 18 that are present in both precancerous and cancerous cells transformed by these HPV types. INOVIO’s lead candidate VGX-3100, currently in Phase III trials for precancerous cervical dysplasia. In the Phase IIb clinical trial the drug demonstrated that it had eliminated high grade dysplasia in nearly 50% of women; in 80% of those whose high grade dysplasia was eliminated, the HPV infection was also cleared by VGX-3100.

• Artesunate: Frantz Viral Therapeutics

Artesunate is a derivative of artemisinin. The drug is self-administered via vaginal inserts (similar to yeast infection treatment), anal suppositories, or as an ointment for pre-cancers of cervical, perianal and vulvar/vaginal tissues respectively. The safe and effective Phase I study of artesunate for the treatment of CIN results are published in Gynecologic Oncology, the journal of the Society of Gynecologic Oncology: A First-in Human Proof-of Concept Trial of Intravaginal Artesunate and were found safe and well-tolerated, at clinically effective doses to treat CIN. Currently, the drug is being evaluated in the Phase II stage of development.

Further product details are provided in the report……..

Cervical Intraepithelial Neoplasia: Therapeutic Assessment

This segment of the report provides insights about the different Cervical Intraepithelial Neoplasia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cervical Intraepithelial Neoplasia
• There are approx. 8+ key companies which are developing the therapies for Cervical Intraepithelial Neoplasia. The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e. phase III include, Inovio Pharmaceuticals.
• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cervical Intraepithelial Neoplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cervical Intraepithelial Neoplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical Intraepithelial Neoplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical Intraepithelial Neoplasia drugs.

Cervical Intraepithelial Neoplasia Report Insights

• Cervical Intraepithelial Neoplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cervical Intraepithelial Neoplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cervical Intraepithelial Neoplasia drugs?
• How many Cervical Intraepithelial Neoplasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical Intraepithelial Neoplasia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical Intraepithelial Neoplasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cervical Intraepithelial Neoplasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Inovio Pharmaceuticals
• Frantz Viral Therapeutics
• Antiva Biosciences
• Genexine, Inc.
• Merck sharp &Dohme

Key Products

• VGX-3100
• Artesunate
• ABI-2280
• GX-188E
• Pembrolizumab